Resumen de acción 1177 Sino Biopharmaceutical Limited, un holding de inversiones, opera como conglomerado farmacéutico de investigación y desarrollo en la República Popular China. Saber más
Recompensas Análisis de riesgos Ver todos los controles de riesgos Captura tus ideas, enlaces y narrativas de la empresa
Competidores de Sino Biopharmaceutical Limited Historial de precios y rendimiento
Resumen de las cotizaciones máximas, mínimas y variaciones del Sino Biopharmaceutical Precios históricos de las acciones Precio actual de la acción HK$3.22 Máximo en las últimas 52 semanas HK$4.25 Mínimo de 52 semanas HK$2.29 Beta 0.69 Cambio en 1 mes -2.42% Variación en 3 meses -6.94% Cambio de 1 año 1.58% Variación en 3 años -40.92% Variación en 5 años -55.61% Variación desde la OPV 11,756.54%
Noticias y actualizaciones recientes
Sino Biopharmaceutical Limited Obtains Permission to Submit Marketing Application for Indication of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsules for Treatment of Advanced Alveolar Soft Part Sarcoma Dec 19
Sino Biopharmaceutical Limited Announces Positive Results from Phase III Study of Benmelstobart Injection with or Without Anlotinib Hydrochloride Capsules as Consolidation Therapy After Chemoradiotherapy for Non-Small Cell Lung Cancer Dec 18
Sino Biopharmaceutical Limited Announces Approval for Marketing of Eribulin Mesilate Injection Dec 11
Is Sino Biopharmaceutical (HKG:1177) A Risky Investment? Dec 08
Sino Biopharmaceutical Limited Announces Approval for Marketing of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsule for the Indication of Treatment for Endometrial Cancer Nov 27
Sino Biopharmaceutical Limited Announces Acceptance of New Indication Application for Marketing of Anlotinib Hydrochloride Capsule in Combination with Penpulimab Injection for First-Line Treatment of Advanced Hepatocellular Carcinoma Nov 21 Ver más actualizaciones
Sino Biopharmaceutical Limited Obtains Permission to Submit Marketing Application for Indication of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsules for Treatment of Advanced Alveolar Soft Part Sarcoma Dec 19
Sino Biopharmaceutical Limited Announces Positive Results from Phase III Study of Benmelstobart Injection with or Without Anlotinib Hydrochloride Capsules as Consolidation Therapy After Chemoradiotherapy for Non-Small Cell Lung Cancer Dec 18
Sino Biopharmaceutical Limited Announces Approval for Marketing of Eribulin Mesilate Injection Dec 11
Is Sino Biopharmaceutical (HKG:1177) A Risky Investment? Dec 08
Sino Biopharmaceutical Limited Announces Approval for Marketing of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsule for the Indication of Treatment for Endometrial Cancer Nov 27
Sino Biopharmaceutical Limited Announces Acceptance of New Indication Application for Marketing of Anlotinib Hydrochloride Capsule in Combination with Penpulimab Injection for First-Line Treatment of Advanced Hepatocellular Carcinoma Nov 21
Sino Biopharmaceutical Limited Announces Approval for Clinical Trials of the Fourth-Generation EGFR Inhibitor "TQB3002" in the United States Nov 14
Sino Biopharmaceutical Limited Announces Acceptance of New Indication Application for Marketing of Anlotinib Hydrochloride Capsules in Combination with Chemotherapy for First-Line Treatment of Advanced Soft Tissue Sarcoma Oct 21
Key Executive recently sold HK$51m worth of stock Oct 07
After Leaping 27% Sino Biopharmaceutical Limited (HKG:1177) Shares Are Not Flying Under The Radar Oct 02
First half 2024 earnings: EPS and revenues exceed analyst expectations Sep 28
Sino Biopharmaceutical Limited Announces Phase III Study Results of Culmerciclib in Combination with Fulvestrant for Treatment of HR+/HER2- Advanced Breast Cancer Following Endocrine Treatment Presented At 2024 CSCO Sep 27
Sino Biopharmaceutical Limited Announces Phase III Study Results of Anlotinib Hydrochloride Capsules in Combination with Penpulimab Injection for First-Line Treatment of Advanced Hepatocellular Cancinoma Was Presented at ESMO 2024 Sep 16
Upcoming dividend of HK$0.03 per share Sep 03
Here's Why Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt Responsibly Sep 02
Sino Biopharmaceutical Limited Announces Positive Results on Phase III Study of Anlotinib Hydrochloride Capsule in Combination with Penpulimab for First-Line Treatment of Advanced Hepatocellular Carcoma Aug 28
Consensus EPS estimates increase by 11% Aug 20
First half 2024 earnings released: EPS: CN¥0.16 (vs CN¥0.068 in 1H 2023) Aug 14 Sino Biopharmaceutical Limited Announces Acceptance of New Indication Application for Marketing of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsule for First-Line Treatment of Advanced Renal Cell Carinoma Aug 01
Sino Biopharmaceutical Limited to Report Q2, 2024 Results on Aug 13, 2024 Jul 31
Sino Biopharmaceutical Limited Announces Interim Analysis of Phase III Clinical Trial of the Categroy 1 Innovative Drug Culmerciclib Capsule Jul 18
Sino Biopharmaceutical Limited Announces Positive Results on Phase III Study of Anlotinib Hydrochloride Capsule in Combination with Chemotherapy for First-Line Treatment of Advanced Soft Tissue Sarcoma Jul 16
Sino Biopharmaceutical Limited Announces Acceptance of New Drug Application for Categroy 1 Innovative Drug Rovadicitinib Tablet Jul 15
Are Investors Undervaluing Sino Biopharmaceutical Limited (HKG:1177) By 48%? Jul 12
Sino Biopharmaceutical Limited Receives Approval for Marketing of Liraglutide Injection Jun 25
Sino Biopharmaceutical Limited Announces Approval for Marketing of Category 1 Innovative Drug Envonalkib Citrate Capsules "Envonalkib (TQ-B3139)" Jun 19 Sino Biopharmaceutical Limited Announces Approval for Marketing of Gadoteridol Injection
Sino Biopharmaceutical Limited Announces Retirement of Ms. Li Mingqin as Executive Director Jun 06
Upcoming dividend of HK$0.03 per share Jun 04
Sino Biopharmaceutical Limited Announces Positive Results on Phase III Study of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsules for First-Line Treatment of Advanced Renal Cell Carcinoma May 24
Here's Why Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt Responsibly May 21
Sino Biopharmaceutical Limited Receives Marketing Approval from National Medical Products Administration of China May 10
Full year 2023 earnings: EPS and revenues miss analyst expectations May 01
Sino Biopharmaceutical Limited Announces Approval for Marketing of Category 1 Unecritinib Fumarate Capsules May 01
Investor sentiment improves as stock rises 18% Apr 26
Executive Chairwoman of the Board recently bought HK$5.8m worth of stock Apr 21
Sino Biopharmaceutical Limited's (HKG:1177) 27% Cheaper Price Remains In Tune With Earnings Apr 21
Consensus revenue estimates fall by 13% Apr 04
What Does The Future Hold For Sino Biopharmaceutical Limited (HKG:1177)? These Analysts Have Been Cutting Their Estimates Apr 03
Sino Biopharmaceutical Limited, Annual General Meeting, Jun 05, 2024 Mar 29
Full year 2023 earnings: EPS and revenues miss analyst expectations Mar 29
Sino Biopharmaceutical Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 5 July 2024 Mar 28
Sino Biopharmaceutical Limited's (HKG:1177) Intrinsic Value Is Potentially 34% Above Its Share Price Mar 20
Sino Biopharmaceutical Limited Provides Update on Development Progress of Mash Products "Lanifibranor" and "TQA2225" Mar 16
Sino Biopharmaceutical Limited Announces Latest Results of Phase II Clinical Study of KRAS G12C Inhibitor Garsorasib Tablet Mar 13
Sino Biopharmaceutical Limited to Report Fiscal Year 2023 Results on Mar 28, 2024 Mar 02
Sino Biopharmaceutical Limited Announces Acceptance of the New Indication Application for Marketing of Anlotinib Hydrochloride Capsules and Anti Pd-L1 Benmelstobart Feb 28
Qingdao Ocean Innovative Products Investment Fund Co., Ltd. and Qingdao Ocean New Kinetic Energy Products Investment Fund (Limited Partnership) agreed to acquire 67% stake in CP Pharmaceutical (Qingdao) Co., Ltd from Sino Biopharmaceutical Limited (SEHK:1177) for CNY 1.8 billion. Feb 08
Sino Biopharmaceutical Limited Announces Prioritised Evaluation Granted for KRAS G12c Inhibitor Garsorasib Tablet (D-1553) Jan 23
Now 21% undervalued Jan 15
Sino Biopharmaceutical Limited Announces Approval of Clinical Trial for Neuropathic Pain Dec 28
Sino Biopharmaceutical Limited Announces Completion of Patient Enrollment in Phase III Clinical Trial of Anlotinib Combined with Chemotherapy in First-Line Treatment of Advanced Soft Tissue Sarcoma Dec 22
Sino Biopharmaceutical Limited Announces Phase I Clinical Research Results of Tqh2722 Dec 12
Sino Biopharmaceutical Limited Announces First Dose of the First Batch of Subjects in Phase I Clinical Trial of TQA3038 Dec 05
An unknown buyer acquired Suzhou Tianqing Xingwei Med./Lianyungang Chia Tai Tianqing Med./Zhejia Tianqing Zhongwei Med. from Sino Biopharmaceutical Limited (SEHK:1177) for approximately CNY 150 million. Nov 10
Investor sentiment improves as stock rises 16% Oct 30
Sino Biopharmaceutical Limited Announces Application for Phase Ib/II Clinical Trial of Innovative Drug Oct 17 An unknown buyer acquired 84.2% stake in Shanghai Chia Tai Tongyong Pharmaceutical Co., Ltd. from Sino Biopharmaceutical Limited (SEHK:1177) for CNY 290 million. Oct 11
Upcoming dividend of HK$0.02 per share at 2.7% yield Sep 27
Sino Biopharmaceutical Limited Announces IND Application of Innovative Medicine TRD205 (AT2R Antibody) Filed with and Accept by FDA Sep 26
First half 2023 earnings released: EPS: CN¥0.068 (vs CN¥0.10 in 1H 2022) Aug 26
Sino Biopharmaceutical Limited Announces Interim Cash Dividend for the Period Ended 30 June 2023, Payable on 27 October 2023 Aug 26
Sino Biopharmaceutical Limited to Report First Half, 2023 Results on Aug 25, 2023 Aug 03
Key Executive recently bought HK$34m worth of stock Jul 04
Sino Biopharmaceutical Limited Announces Application for Marketing of Loxoprofen Sodium Cataplasms Jul 01
Upcoming dividend of HK$0.06 per share at 3.0% yield Jun 13
Sino Biopharmaceutical Limited Announces New Drug Marketing Application for the Category 1 Innovative Anti-Tumor Medicine May 24
Sino Biopharmaceutical Limited Announces Approval for Marketing by National Medical Products Administration of China for F-627 (Efbemalenograstim alfa Injection) May 11
Executive Vice Chairwoman of the Board recently bought HK$21m worth of stock Apr 06
Full year 2022 earnings: EPS and revenues miss analyst expectations Apr 01
Sino Biopharmaceutical Limited Announces Clinical Trial Application of Innovative Medicine "Tqb2103 (Claudin18.2 ADC)" Accepted by Center for Drug Evaluation Feb 11
Sino Biopharmaceutical Limited Announces Application for Marketing of Category I Innovative Drug Tqb2450 Injection in Combination with Anlotinib Hydrochloride Capsules for the Indication of First-Line Treatment of Small Cell Lung Cancer Jan 14
Sino Biopharmaceutical Limited Announces the Enrollment of All Patients in Phase III Clinical Trial of "Tqg203" Dec 10
Less than half of directors are independent Nov 16 Sino Biopharmaceutical Limited Provides Revenue Guidance for 2023
Investor sentiment improved over the past week Oct 18
Upcoming dividend of HK$0.06 per share Aug 30
Sino Biopharmaceutical Limited Announces Interim Cash Dividend for the period ended 30 June 2022, Payable on 28 September 2022 Aug 24
First half 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Aug 24
Sino Biopharmaceutical Limited to Report First Half, 2022 Results on Aug 23, 2022 Aug 12 Sino Biopharmaceutical Limited Announces CEO Changes, Effective July 28, 2022
Sino Biopharmaceutical Limited Announces Application for Marketing of Category 1 Anti-Tumor Innovative Drug TQ-B3101 Capsule Jun 28
Sino Biopharmaceutical Limited Announces Approval of Category 1 Innovative Drug TQC2938 Injection for Clinical Trial Jun 15
Upcoming dividend of HK$0.04 per share Jun 08 Rentabilidad de los accionistas 1177 HK Pharmaceuticals Mercado HK 7D 0.6% -1.9% -0.5% 1Y 1.6% -3.9% 19.9%
Ver rendimientos de los accionistas
Rentabilidad vs. Industria: 1177 superó a la industria Hong Kong Pharmaceuticals, que obtuvo un rendimiento del -3.9% el año pasado.
Rentabilidad vs. Mercado: 1177 obtuvo unos resultados inferiores a los del mercado Hong Kong, que fueron del 19.9% el año pasado.
Volatilidad de los precios Is 1177's price volatile compared to industry and market? 1177 volatility 1177 Average Weekly Movement 5.4% Pharmaceuticals Industry Average Movement 6.4% Market Average Movement 8.8% 10% most volatile stocks in HK Market 18.6% 10% least volatile stocks in HK Market 4.1%
Precio estable de las acciones: 1177 no ha tenido una volatilidad de precios significativa en los últimos 3 meses.
Volatilidad a lo largo del tiempo: La volatilidad semanal de 1177 (5%) se ha mantenido estable durante el año pasado.
Acerca de la empresa Sino Biopharmaceutical Limited, un holding de inversiones, opera como conglomerado farmacéutico de investigación y desarrollo en la República Popular China. Opera a través de tres segmentos: Medicamentos chinos modernizados y medicamentos químicos, Inversión y Otros. La empresa ofrece medicamentos oncológicos, como las cápsulas de clorhidrato de anlotinib de la marca Focus V, la inyección de penpulimab de la marca Annike, la inyección de efbemalenograstina alfa de la marca Yilishu, las cápsulas de pomalidomida de la marca Anyue, la inyección de bevacizumab de la marca Anbeisi, la inyección de rituximab de la marca Delituo y el trastuzumab inyectable de la marca Saituo; medicamentos para enfermedades hepáticas, como la inyección de isoglicirricinato de magnesio de la marca Tianqing Ganmei y los comprimidos dispersables de entecavir de la marca Runzhong; y medicamentos para el aparato respiratorio, como la suspensión de budesonida para inhalación de la marca Tianqing suchang y el colistimetato sódico inyectable de la marca Tianyun.
Mostrar más Resumen de fundamentos de Sino Biopharmaceutical Limited ¿Cómo se comparan los beneficios e ingresos de Sino Biopharmaceutical con su capitalización de mercado? Estadísticas fundamentales de 1177 Capitalización bursátil HK$58.44b Beneficios(TTM ) HK$2.28b Ingresos (TTM ) HK$29.59b
25.7x Ratio precio-beneficio (PE)
2.0x Ratio precio-ventas (PS) Beneficios e Ingresos Estadísticas clave de rentabilidad del último informe de resultados (TTM) Cuenta de resultados (TTM ) de 1177 Ingresos CN¥27.79b Coste de los ingresos CN¥5.23b Beneficio bruto CN¥22.56b Otros gastos CN¥20.41b Beneficios CN¥2.14b
Últimos beneficios comunicados
Jun 30, 2024
Próxima fecha de beneficios
n/a
Beneficios por acción (BPA) 0.12 Margen bruto 81.16% Margen de beneficio neto 7.71% Ratio deuda/patrimonio 22.6%
¿Cómo se ha desempeñado 1177 a largo plazo?
Ver rendimiento histórico y comparativa Dividendos
1.8% Rentabilidad actual por dividendo
Análisis de la empresa y estado de los datos financieros Datos Última actualización (huso horario UTC) Análisis de la empresa 2024/12/23 15:06 Precio de las acciones al final del día 2024/12/23 00:00 Beneficios 2024/06/30 Ingresos anuales 2023/12/31
Fuentes de datos Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC . Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
Paquete Datos Marco temporal Ejemplo Fuente EE.UU. * Finanzas de la empresa 10 años Cuenta de resultados Estado de tesorería Balance Estimaciones del consenso de analistas +3 años Previsiones financieras Objetivos de precios de los analistas Precios de mercado 30 años Precios de las acciones Dividendos, escisiones y acciones Propiedad 10 años Accionistas principales Información privilegiada Gestión 10 años Equipo directivo Consejo de Administración Principales avances 10 años
* ejemplo para los valores estadounidenses, para los no estadounidenses se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Obtenga más información aquí .
Modelo de análisis y copo de nieve Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github , también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube .
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en .
Fuentes analistas Sino Biopharmaceutical Limited está cubierta por 51 analistas. 23 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
Analista Institución Justin Liu BNP Paribas Securities (Asia) Ling Zhang BNP Paribas Securities (Asia) Wai Chak Yuen BOCI Research Ltd.
Mostrar 48 más analistas 
